<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01239472</url>
  </required_header>
  <id_info>
    <org_study_id>CRAD001ABR14T</org_study_id>
    <nct_id>NCT01239472</nct_id>
  </id_info>
  <brief_title>Cytokines Evaluation in Early Calcineurin Inhibitors Withdrawn on Renal Transplant</brief_title>
  <official_title>Cytokines Evaluation in Early Calcineurin Inhibitors Withdrawn on Renal Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Andre Barreto Pereira</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Santa Casa de Misericórdia de Belo Horizonte</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Currently, acute kidney injury is diagnosed by increased serum creatinine. However,
      creatinine is not a reliable marker for acute changes in renal function.

      The biology of the renal graft is influenced by chemokines from reperfusion (just after the
      kidney transplant) and throughout its course, when acute and chronic inflammatory changes
      occurs. Moreover, the evaluation of changes in urinary cytokines reflects kidney interstitial
      patterns, and can predict renal function, acute rejection episodes and their response to
      treatment.

      Today there are several studies comparing the relative immunosuppression of renal function,
      but few noticed its relationship with cytokines and chemokines. Thus, we proposed studying
      the inflammatory consequences of early calcineurin inhibitors (ICN) withdrawing in transplant
      patients by urine analysis. Kidney biopsy was done before ICN withdrawn and replaced by
      everolimus (3 months after transplant), and 1 year after transplant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Research objectives

           OBJECTIVES

           Main Objectives:

           • Evaluate the urinary chemokines in kidney transplant patients taking prednisone,
           tacrolimus and mycophenolate sodium compared to those in use prednisone, mycophenolate
           sodium and everolimus as maintenance immunosuppression.

           Secondary Objectives:

           • Assess renal function (serum creatinine and its clearance estimated by the
           Cockcroft-Gault) and a composite outcome (acute rejection, graft loss, death and
           abandonment of the study) in patients taking prednisone, tacrolimus and mycophenolate
           sodium compared to those taking prednisone, mycophenolate sodium and everolimus as
           maintenance immunosuppression.

        2. Scientific background, relevance and justification of the research

      In current clinical practice, acute kidney injury is typically diagnosed by measuring serum
      creatinine. Unfortunately, creatinine is an unreliable indicator during acute changes in
      kidney function. First, serum creatinine concentrations may not change until about 50% of
      kidney function has already been lost. Second, serum creatinine does not accurately depict
      kidney function until a steady state has been reached, which may require several days.
      Chemokines can influence at least three aspects of the biology of the renal graft: 1 - the
      restoration of blood flow in the graft can lead to injury type ischemia / reperfusion in
      which chemokines recruit leukocytes; 2 - receptor responses to infection during immune
      suppression involve chemokines and 3 - the inflammatory components in the acute rejection
      (RA) and interstitial fibrosis / tubular atrophy (IF/TA) are controlled by chemokines.

      Current data have showed urinary cytokines predicting renal function by months in renal
      transplanted patients. In the evaluation of urinary cytokines and chemokines in the presence
      of acute rejection, taken together the studies reported elevations of urinary levels of
      Protein-3 alpha (MIP-3α/CCL20), interleuxin-8 (IL-8/CXCL8), interleuxin-6 (IL-6), tumoral
      necrosis factor (TNF), interleukin- 10 (IP-10), interferon (IFN), monocyte chemoattractant
      protein-1 (MCP-1 / CCL2), Interferon gamma-induced protein 10 (IL-10), Monokine induced by
      gamma interferon (MIG/CXCL9), Interferon-inducible T-cell alpha chemoattractant
      (I-TAC/CXCL11), regulated upon activation normal T cell expressed and secreted (RANTES/CCL5).
      As predictors of complications and future changes in renal function, levels of Transforming
      growth factor beta (TGF-β) and interferon-gamma inducible protein 10 (IP-10/CXCL10) were
      associated with renal function 6 months and 4 years after transplantation (15-16).
      IP-10/CXCL10, MIG/CXCL9, G protein-coupled receptor 9 (GPR9/CXCR3), RANTES/CCL5 and the
      percentage of binding of interleukin-2 (IL-2) were associated with the occurrence of RA.
      IP-10/CXCL10 and MIG/CXCL9 were also considered useful as predictors of response to treatment
      of RA. Nankivell et al reported in 2003 that after 1year of renal transplant, 94% of patients
      present with chronic rejection grade I (BANFF score) and 76% present with calcineurin
      nephrotoxicity, although there is insufficient data about urinary cytokines at these
      situations. And adding new information, Hu et al reported in 2009 urinary major intrinsic
      protein-delta (MIP-δ), osteoprotegerin (OPG), IP-10/CXCL10, MIG/CXCL9 as good biomarkers for
      acute renal rejection and IF/TA.

      Nowadays there is a lot of studies comparing immunosuppression in relation to renal function
      but not so much in relation to chemokines and cytokines, which are more representative of
      allograft inflammation and fibrosis.

      So, we proposed studying the inflammatory consequences of early CNI withdrawn in renal
      transplant patients before the immunosuppression modification (3 months after transplant) and
      1 year after kidney transplant.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cytokines Evaluation</measure>
    <time_frame>Urine and biopsy data are collected 90 days and 365 days after transplant.</time_frame>
    <description>Cd106(VCAM-1) , IP-10/CXCL10, MIG/CXCL9, MCP-1/CCL2, IL-1, RANTES, IL-8, IL12p70, TNF, IL-10, IL-6, IL-1, VEGF, FGF, CD54(ICAM-1) were analysed in urine 90 days after transplant (before randomization), and 365 days after transplant. Material were conserved at -80 Celsius, and analysed by ELISA at same time. Data was shown in MFI units</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Renal Function</measure>
    <time_frame>90 days after transplant and 365 days after transplant</time_frame>
    <description>Evaluation of renal function (serum creatinine) 90 days after transplant and 365 days after transplant.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Renal Transplant Rejection</condition>
  <condition>Immunosuppression</condition>
  <arm_group>
    <arm_group_label>tacrolimus</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Kidney transplant patients with living or deceased donors using tacrolimus, mycophenolate sodium and prednisone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>everolimus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Kidney transplant patients with living or deceased donors using tacrolimus, mycophenolate sodium and prednisone, and converted for everolimus, mycophenolate sodium, and prednisone 90 days after renal transplantation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>Replacement of tacrolimus by everolimus, 30 days after transplat. It was done after kidney biopsy (excluding acute rejection), blood and urine analysis.</description>
    <arm_group_label>everolimus</arm_group_label>
    <other_name>Certican</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients over 18 years old and under 65 years old

          -  Recipients of first kidney transplant

          -  Donor younger than 65 years old

          -  PRA (panel reactive antigen) ≤ 30% in class I or class II

          -  No acute rejection episodes

          -  Proteinuria &lt;1000 mg / day

        Exclusion Criteria:

          -  multiple organ transplant recipient

          -  Chronic liver failure

          -  Asymptomatic bacteriuria or urinary infection at randomization time

          -  Creatinine ≥ 2 mg / dL at randomization time (90 days after transplant)

          -  Presence of uncontrolled hypercholesterolemia (≥ 350 mg / dL, ≥ 9.1 mmol / L) or
             hypertriglyceridemia (≥ 500 mg / dL, ≥ 5.6 mmol / L) at randomization time (90 days
             after transplant)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andre B Pereira, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Marieta Konder Bornhausen Hospital and Maternity</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Santa Casa de Misericórdia de Belo Horizonte</name>
      <address>
        <city>Belo Horizonte</city>
        <state>Minas Gerais</state>
        <zip>30150221</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Devarajan P. Emerging biomarkers of acute kidney injury. Contrib Nephrol. 2007;156:203-12. Review.</citation>
    <PMID>17464129</PMID>
  </reference>
  <reference>
    <citation>Hu H, Knechtle SJ. Elevation of multiple cytokines/chemokines in urine of human renal transplant recipients with acute and chronic injuries: potential usage for diagnosis and monitoring. Transpl Rev 2006;20:165-71</citation>
  </reference>
  <reference>
    <citation>Rüster M, Sperschneider H, Fünfstück R, Stein G, Gröne HJ. Differential expression of beta-chemokines MCP-1 and RANTES and their receptors CCR1, CCR2, CCR5 in acute rejection and chronic allograft nephropathy of human renal allografts. Clin Nephrol. 2004 Jan;61(1):30-9.</citation>
    <PMID>14964455</PMID>
  </reference>
  <reference>
    <citation>Sibbring JS, Sharma A, McDicken IW, Sells RA, Christmas SE. Localization of C-X-C and C-C chemokines to renal tubular epithelial cells in human kidney transplants is not confined to acute cellular rejection. Transpl Immunol. 1998 Dec;6(4):203-8.</citation>
    <PMID>10342733</PMID>
  </reference>
  <reference>
    <citation>Di Paolo S, Gesualdo L, Stallone G, Ranieri E, Schena FP. Renal expression and urinary concentration of EGF and IL-6 in acutely dysfunctioning kidney transplanted patients. Nephrol Dial Transplant. 1997 Dec;12(12):2687-93.</citation>
    <PMID>9430873</PMID>
  </reference>
  <reference>
    <citation>Smith SD, Wheeler MA, Lorber MI, Weiss RM. Temporal changes of cytokines and nitric oxide products in urine from renal transplant patients. Kidney Int. 2000 Aug;58(2):829-37.</citation>
    <PMID>10916108</PMID>
  </reference>
  <reference>
    <citation>Jiménez R, Ramírez R, Carracedo J, Agüera M, Navarro D, Santamaría R, Pérez R, Del Castillo D, Aljama P. Cytometric bead array (CBA) for the measurement of cytokines in urine and plasma of patients undergoing renal rejection. Cytokine. 2005 Oct 7;32(1):45-50.</citation>
    <PMID>16153856</PMID>
  </reference>
  <reference>
    <citation>Prodjosudjadi W, Daha MR, Gerritsma JS, Florijn KW, Barendregt JN, Bruijn JA, van der Woude FJ, van Es LA. Increased urinary excretion of monocyte chemoattractant protein-1 during acute renal allograft rejection. Nephrol Dial Transplant. 1996 Jun;11(6):1096-103.</citation>
    <PMID>8671975</PMID>
  </reference>
  <reference>
    <citation>Grandaliano G, Gesualdo L, Ranieri E, Monno R, Stallone G, Schena FP. Monocyte chemotactic peptide-1 expression and monocyte infiltration in acute renal transplant rejection. Transplantation. 1997 Feb 15;63(3):414-20.</citation>
    <PMID>9039933</PMID>
  </reference>
  <reference>
    <citation>Hu H, Aizenstein BD, Puchalski A, Burmania JA, Hamawy MM, Knechtle SJ. Elevation of CXCR3-binding chemokines in urine indicates acute renal-allograft dysfunction. Am J Transplant. 2004 Mar;4(3):432-7.</citation>
    <PMID>14961998</PMID>
  </reference>
  <reference>
    <citation>Kanmaz T, Feng P, Torrealba J, Kwun J, Fechner JH, Schultz JM, Dong Y, Kim HT, Dar W, Hamawy MM, Knechtle SJ, Hu H. Surveillance of acute rejection in baboon renal transplantation by elevation of interferon-gamma inducible protein-10 and monokine induced by interferon-gamma in urine. Transplantation. 2004 Oct 15;78(7):1002-7.</citation>
    <PMID>15480165</PMID>
  </reference>
  <reference>
    <citation>Hauser IA, Spiegler S, Kiss E, Gauer S, Sichler O, Scheuermann EH, Ackermann H, Pfeilschifter JM, Geiger H, Gröne HJ, Radeke HH. Prediction of acute renal allograft rejection by urinary monokine induced by IFN-gamma (MIG). J Am Soc Nephrol. 2005 Jun;16(6):1849-58. Epub 2005 Apr 27.</citation>
    <PMID>15857922</PMID>
  </reference>
  <reference>
    <citation>Kotsch K, Mashreghi MF, Bold G, Tretow P, Beyer J, Matz M, Hoerstrup J, Pratschke J, Ding R, Suthanthiran M, Volk HD, Reinke P. Enhanced granulysin mRNA expression in urinary sediment in early and delayed acute renal allograft rejection. Transplantation. 2004 Jun 27;77(12):1866-75.</citation>
    <PMID>15223905</PMID>
  </reference>
  <reference>
    <citation>Sorrentino S, Landmesser U. Nonlipid-lowering effects of statins. Curr Treat Options Cardiovasc Med. 2005 Dec;7(6):459-66.</citation>
    <PMID>16283973</PMID>
  </reference>
  <reference>
    <citation>Yamada K, Hatakeyama E, Arita S, Sakamoto K, Kashiwabara H, Hamaguchi K. Prediction of chronic renal allograft dysfunction from evaluations of TGFBeta1 and the renin-angiotensin system. Clin Exp Nephrol. 2003 Sep;7(3):238-42.</citation>
    <PMID>14586721</PMID>
  </reference>
  <reference>
    <citation>Teppo AM, Honkanen E, Finne P, Törnroth T, Grönhagen-Riska C. Increased urinary excretion of alpha1-microglobulin at 6 months after transplantation is associated with urinary excretion of transforming growth factor-beta1 and indicates poor long-term renal outcome. Transplantation. 2004 Sep 15;78(5):719-24.</citation>
    <PMID>15371675</PMID>
  </reference>
  <reference>
    <citation>Tatapudi RR, Muthukumar T, Dadhania D, Ding R, Li B, Sharma VK, Lozada-Pastorio E, Seetharamu N, Hartono C, Serur D, Seshan SV, Kapur S, Hancock WW, Suthanthiran M. Noninvasive detection of renal allograft inflammation by measurements of mRNA for IP-10 and CXCR3 in urine. Kidney Int. 2004 Jun;65(6):2390-7.</citation>
    <PMID>15149352</PMID>
  </reference>
  <reference>
    <citation>Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med. 2003 Dec 11;349(24):2326-33.</citation>
    <PMID>14668458</PMID>
  </reference>
  <reference>
    <citation>Hu H, Kwun J, Aizenstein BD, Knechtle SJ. Noninvasive detection of acute and chronic injuries in human renal transplant by elevation of multiple cytokines/chemokines in urine. Transplantation. 2009 Jun 27;87(12):1814-20. doi: 10.1097/TP.0b013e3181a66b3e.</citation>
    <PMID>19543058</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>November 10, 2010</study_first_submitted>
  <study_first_submitted_qc>November 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2010</study_first_posted>
  <results_first_submitted>March 29, 2018</results_first_submitted>
  <results_first_submitted_qc>September 26, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 21, 2019</results_first_posted>
  <last_update_submitted>January 28, 2020</last_update_submitted>
  <last_update_submitted_qc>January 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Santa Casa de Misericórdia de Belo Horizonte</investigator_affiliation>
    <investigator_full_name>Andre Barreto Pereira</investigator_full_name>
    <investigator_title>MD, Msc, PhD</investigator_title>
  </responsible_party>
  <keyword>chronic allograft nephropathy</keyword>
  <keyword>cytokines</keyword>
  <keyword>kidney transplant</keyword>
  <keyword>calcineurin inhibitors withdrawn</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All collected IPD will be shared in this website, and in the publication that is already being written.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Data are already available in this website, and will keep available with the PI for 1 year after the publication.</ipd_time_frame>
    <ipd_access_criteria>All data will be available in this website and with the PI, Dr Andre Barreto Pereira, by his e-mail.</ipd_access_criteria>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Tacrolimus</title>
          <description>Kidney transplant patients taking tacrolimus, mycophenolate sodium and prednisone the whole study</description>
        </group>
        <group group_id="P2">
          <title>Everolimus</title>
          <description>Kidney transplant patients taking tacrolimus, mycophenolate sodium and prednisone, whom switched tacrolimus to everolimus 90 days after renal transplantation. Since then the patients kept taking everolimus, mycophenolate sodium and prednisone</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Urine and biopsy data are collected 90 days and 365 days after transplant. Other clinical data as Creatinine, patient information were collected monthly until 365 days after transplant. Among 22 patients included in the study, some urine were lost and couldn't therefore be analysed</population>
      <group_list>
        <group group_id="B1">
          <title>Tacrolimus</title>
          <description>Kidney transplant patients taking tacrolimus, mycophenolate sodium and prednisone with low immunologic risk .</description>
        </group>
        <group group_id="B2">
          <title>Everolimus</title>
          <description>Kidney transplant patients taking tacrolimus, mycophenolate sodium and prednisone with low immunologic risk, and converted for use of mycophenolate sodium, everolimus, and prednisone after 90 days of kidney transplantation.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cytokines Evaluation</title>
        <description>Cd106(VCAM-1) , IP-10/CXCL10, MIG/CXCL9, MCP-1/CCL2, IL-1, RANTES, IL-8, IL12p70, TNF, IL-10, IL-6, IL-1, VEGF, FGF, CD54(ICAM-1) were analysed in urine 90 days after transplant (before randomization), and 365 days after transplant. Material were conserved at -80 Celsius, and analysed by ELISA at same time. Data was shown in MFI units</description>
        <time_frame>Urine and biopsy data are collected 90 days and 365 days after transplant.</time_frame>
        <population>15 patients were enrolled in each group. However in &quot;tacrolimus&quot; group 5 patients didn’t want to be submitted to other biopsy and to collect urine 365 days after transplant. And in &quot;everolimus&quot; group 3 patients had adverse events and was switched back to tacrolimus.</population>
        <group_list>
          <group group_id="O1">
            <title>Tacrolimus</title>
            <description>Kidney transplant patients taking tacrolimus, mycophenolate sodium and prednisone, during the whole study. This is the no intervention group.</description>
          </group>
          <group group_id="O2">
            <title>Everolimus</title>
            <description>Kidney transplant patients taking tacrolimus, mycophenolate sodium and prednisone at beginning, but whom switched tacrolimus to everolimus at 90 days after transplant. This is the intervention group</description>
          </group>
        </group_list>
        <measure>
          <title>Cytokines Evaluation</title>
          <description>Cd106(VCAM-1) , IP-10/CXCL10, MIG/CXCL9, MCP-1/CCL2, IL-1, RANTES, IL-8, IL12p70, TNF, IL-10, IL-6, IL-1, VEGF, FGF, CD54(ICAM-1) were analysed in urine 90 days after transplant (before randomization), and 365 days after transplant. Material were conserved at -80 Celsius, and analysed by ELISA at same time. Data was shown in MFI units</description>
          <population>15 patients were enrolled in each group. However in &quot;tacrolimus&quot; group 5 patients didn’t want to be submitted to other biopsy and to collect urine 365 days after transplant. And in &quot;everolimus&quot; group 3 patients had adverse events and was switched back to tacrolimus.</population>
          <units>MFI</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IP10 90days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="380" lower_limit="261" upper_limit="900"/>
                    <measurement group_id="O2" value="893" lower_limit="194" upper_limit="1825"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IP10 365days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="763" lower_limit="88" upper_limit="1668"/>
                    <measurement group_id="O2" value="147" lower_limit="127" upper_limit="353"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCP1 90days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2349" lower_limit="1751" upper_limit="3234"/>
                    <measurement group_id="O2" value="4119" lower_limit="2652" upper_limit="7529"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCP1 365days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1306" lower_limit="750" upper_limit="7259"/>
                    <measurement group_id="O2" value="1375" lower_limit="790" upper_limit="3342"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MIG 90days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="396" lower_limit="239" upper_limit="673"/>
                    <measurement group_id="O2" value="433" lower_limit="249" upper_limit="1925"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MIG 365days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="287" lower_limit="153" upper_limit="964"/>
                    <measurement group_id="O2" value="580" lower_limit="262" upper_limit="1090"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RANTES 90days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148" lower_limit="134" upper_limit="167"/>
                    <measurement group_id="O2" value="145" lower_limit="134" upper_limit="212"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RANTES 365days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144" lower_limit="134" upper_limit="199"/>
                    <measurement group_id="O2" value="155" lower_limit="151" upper_limit="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL8 90days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="495" lower_limit="328" upper_limit="804"/>
                    <measurement group_id="O2" value="624" lower_limit="409" upper_limit="1019"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL8 365days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="641" lower_limit="327" upper_limit="1874"/>
                    <measurement group_id="O2" value="435" lower_limit="321" upper_limit="558"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL12 90days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116" lower_limit="110" upper_limit="121"/>
                    <measurement group_id="O2" value="124" lower_limit="111" upper_limit="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL12 365days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124" lower_limit="119" upper_limit="133"/>
                    <measurement group_id="O2" value="124" lower_limit="119" upper_limit="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF 90days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136" lower_limit="134" upper_limit="145"/>
                    <measurement group_id="O2" value="146" lower_limit="141" upper_limit="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF 365days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="153" lower_limit="150" upper_limit="164"/>
                    <measurement group_id="O2" value="157" lower_limit="151" upper_limit="167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL10 90days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="155" lower_limit="150" upper_limit="168"/>
                    <measurement group_id="O2" value="164" lower_limit="160" upper_limit="173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL10 365 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="179" lower_limit="168" upper_limit="188"/>
                    <measurement group_id="O2" value="182" lower_limit="177" upper_limit="186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL6 90days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="282" lower_limit="224" upper_limit="334"/>
                    <measurement group_id="O2" value="349" lower_limit="224" upper_limit="349"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL6 365days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="281" lower_limit="223" upper_limit="418"/>
                    <measurement group_id="O2" value="262" lower_limit="237" upper_limit="281"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL1 90days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="212" lower_limit="194" upper_limit="234"/>
                    <measurement group_id="O2" value="215" lower_limit="195" upper_limit="224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL1 365days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="228" lower_limit="209" upper_limit="258"/>
                    <measurement group_id="O2" value="228" lower_limit="226" upper_limit="242"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VEGF 90days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82" lower_limit="67" upper_limit="107"/>
                    <measurement group_id="O2" value="70" lower_limit="57" upper_limit="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VEGF 365days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84" lower_limit="46" upper_limit="141"/>
                    <measurement group_id="O2" value="45" lower_limit="33" upper_limit="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FGF 90days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39" lower_limit="35" upper_limit="44"/>
                    <measurement group_id="O2" value="43" lower_limit="37" upper_limit="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FGF 365days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30" lower_limit="26" upper_limit="37"/>
                    <measurement group_id="O2" value="29" lower_limit="23" upper_limit="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD106 90days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43222" lower_limit="33422" upper_limit="59960"/>
                    <measurement group_id="O2" value="28564" lower_limit="9732" upper_limit="55116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD106 365days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18324" lower_limit="12261" upper_limit="54026"/>
                    <measurement group_id="O2" value="19614" lower_limit="11721" upper_limit="26523"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD54 90days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1512" lower_limit="746" upper_limit="2594"/>
                    <measurement group_id="O2" value="1293" lower_limit="666" upper_limit="4206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD54 365days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="696" lower_limit="217" upper_limit="1321"/>
                    <measurement group_id="O2" value="1664" lower_limit="1309" upper_limit="2319"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Renal Function</title>
        <description>Evaluation of renal function (serum creatinine) 90 days after transplant and 365 days after transplant.</description>
        <time_frame>90 days after transplant and 365 days after transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tacrolimus</title>
            <description>Kidney transplant patients with living donors starting with the use of tacrolimus, mycophenolate sodium and prednisone without induction.</description>
          </group>
          <group group_id="O2">
            <title>Everolimus</title>
            <description>Kidney transplant patients with living donors starting with the use of tacrolimus, mycophenolate sodium and prednisone without induction, and converted for use of mycophenolate sodium, everolimus, and prednisone after 90 days of kidney transplantation.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Renal Function</title>
          <description>Evaluation of renal function (serum creatinine) 90 days after transplant and 365 days after transplant.</description>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cr 90days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="1.2" upper_limit="1.7"/>
                    <measurement group_id="O2" value="1.3" lower_limit="1.05" upper_limit="1.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cr 365days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="1.22" upper_limit="1.65"/>
                    <measurement group_id="O2" value="1.4" lower_limit="0.95" upper_limit="1.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events data were collected during the followup of the study, which was done until the last biopsy, 1 year after transplant.</time_frame>
      <desc>Because the access to patients and files by the PI were limited as previous explained, serious adverses events were considered all cause mortality, and graft failure. Other adverse event was biopsy acute rejection. Withdrawn of the study by patient option, or because everolimus serum level was not reached, was recorded but not considered a adverse event. Hospitalizations were not considered adverse events because sometimes it weren't recorded by the office, and not reported to the PI.</desc>
      <group_list>
        <group group_id="E1">
          <title>Tacrolimus</title>
          <description>Kidney transplant patients starting taking tacrolimus, mycophenolate sodium and prednisone, and keeping it the whole study.</description>
        </group>
        <group group_id="E2">
          <title>Everolimus</title>
          <description>Kidney transplant patients taking tacrolimus, mycophenolate sodium and prednisone, and whom switched tacrolimus to everolimus 90 days after renal transplantation. Therefore the patients were taking everolimus, mycophenolate sodium and prednisone since 90 days after the transplant, and kept this way during the whole study</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>graft failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>biopsy proven acute rejection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Principal Investigator was out of Santa Casa de Misericordia de Belo Horizonte in the periods august-2012 to september-2013, and after december-2014. Data was so restricted mainly to cytokine analysis, acute rejection, graft failure and mortality.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr Andre Barreto Pereira</name_or_title>
      <organization>Hospital e Maternidade Marieta Konder Bornhausen</organization>
      <phone>+55 47 984482826</phone>
      <email>andrebarper@yahoo.com.br</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

